-
公开(公告)号：EP4015534A1
公开(公告)日：2022-06-22
申请号：EP21201788.3
申请日：2015-12-04
发明人： BRENTJENS, Renier J. , SMITH, Eric L. , LIU, Cheng , LIU, Hong
IPC分类号： C07K16/28 , C07K14/725 , C12N5/10 , A61P35/00 , A61P43/00
摘要： The presently disclosed subject matter provides for methods and compositions for treating multiple myeloma. It relates to chimeric antigen receptors (CARs) that specifically target a G-protein coupled receptor ( e.g ., a G-protein coupled receptor family C group 5 member D (GPRC5D)), and immunoresponsive cells comprising such CARs. The presently disclosed CARs targeting a G-protein coupled receptor ( e.g ., GPRC5D) have enhanced immune-activating properties, including anti-tumor activity.
-
2.发明公开T CELL RECEPTOR-LIKE ANTIBODY AGENTS SPECIFIC FOR EBV LATENT MEMBRANE PROTEIN 2A PEPTIDE PRESENTED BY HUMAN HLA 审中-公开T细胞受体样抗体特异性EBV潜伏膜蛋白2A肽由人类HLA呈递
公开(公告)号：EP3307319A2
公开(公告)日：2018-04-18
申请号：EP16808304.6
申请日：2016-06-09
发明人： CHEUNG, Nai-Kong V. , AHMED, Mahiuddin , LOPEZ-ALBAITERO, Andres , LIU, Cheng , LIU, Hong , XIANG, Jingyi , YAN, Su
IPC分类号： A61K39/395 , A61K39/42 , A61P31/22 , C07K16/08 , C07K16/28
CPC分类号： C07K16/468 , A61K2039/505 , A61K2039/572 , C07K16/085 , C07K16/2809 , C07K2317/21 , C07K2317/31 , C07K2317/32 , C07K2317/33 , C07K2317/34 , C07K2317/40 , C07K2317/41 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C07K2317/732 , C07K2317/92 , G01N33/6854
摘要： Described herein are antibodies, fragments thereof and multi-specific binding agents that bind an Epstein-Barr virus (EBV) latent membrane protein 2 (LMP2) peptide presented by HLA class I molecules, in particular, HLA-A02. Also provided herein are methods of using the same or compositions thereof for the detection, prevention and/or therapeutic treatment of diseases characterized by expression of an EBV-LMP2 peptide presented by HLA-A02, in particular, Burkit's lymphoma, Hodgkin's lymphoma and nasopharyngeal carcinoma.
-
公开(公告)号：EP3297673A2
公开(公告)日：2018-03-28
申请号：EP16800529.6
申请日：2016-05-20
发明人： SCHEINBERG, David, A. , DAO, Tao , LIU, Cheng , LIU, Hong , XU, Yiyang , YAN, Su
IPC分类号： A61K39/395 , C07K16/28 , C07K16/18 , C07K16/30
CPC分类号： C07K16/28 , A61K39/0011 , A61K47/6849 , A61K2039/505 , A61K2039/5156 , A61K2039/5158 , C07K14/00 , C07K16/2809 , C07K16/2833 , C07K16/30 , C07K16/3053 , C07K2317/21 , C07K2317/31 , C07K2317/32 , C07K2317/34 , C07K2317/41 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C07K2317/732 , C07K2319/03 , C07K2319/33 , C07K2319/74 , G01N33/57492 , G01N2333/705
摘要： The presently disclosed subject matter provides antigen-binding proteins that specifically bind to Preferentially expressed antigen of melanoma (PRAME), including humanized, chimeric and fully human antibodies against PRAME, antibody fragments (e.g., scFv, Fab and F(ab)2), chimeric antigen receptors (CARs), fusion proteins, and conjugates thereof. The antigen-binding proteins and antibodies bind to a PRAME peptide/HLA class I molecule complex. Such antibodies, fragments, fusion proteins and conjugates thereof are useful for the treatment of PRAME associated diseases, including for example, breast cancer, ovarian cancer, melanoma, lung cancer, gastrointestinal cancer, brain tumor, head and neck cancer, renal cancer, myeloma, neuroblastoma, mantle cell lymphoma, chronic myelocytic leukemia, multiple myeloma, acute lymphoblastic leukemia (ALL), acute myeloid/myelogenous leukemia (AML), Non-Hodgkin lymphoma (NHL), and Chronic lymphocytic leukemia (CLL). The antibodies or antigen binding proteins may comprise one or more framework region amino acid substitutions designed to improve protein stability, antibody binding and/or expression levels.
-
公开(公告)号：EP3880714A1
公开(公告)日：2021-09-22
申请号：EP19884480.5
申请日：2019-11-14
发明人： SPRIGGS, David , MORALES, Javier , NAKANO, Yoko , LIU, Hong
-
公开(公告)号：EP3066131A1
公开(公告)日：2016-09-14
申请号：EP14810051.4
申请日：2014-11-07
发明人： SCHEINBERG, David , VEOMETT, Nicholas , LIU, Hong , XIANG, Jingyi , LIU, Cheng , DAO, Tao , HUET, Heather, Adkins
IPC分类号： C07K16/32 , A61K39/395 , A61P35/00 , A61P35/02 , A01K67/027
CPC分类号： C07K16/32 , A01K2227/105 , A01K2267/0387 , A61K2039/505 , C07K2317/21 , C07K2317/41 , C07K2317/72 , C07K2317/732 , C07K2317/92 , C07K2317/94
摘要： The present disclosure relates to an anti-WT-1/HLA/A2 antibody with enhanced antibody dependent cell-mediated cytotoxicity (ADCC) function due to altered Fc glycosylation. The antibody, which has reduced fucose and/or galactose, was compared to its normally glycosylated counterpart in binding assays,
in vitro ADCC assays, and mesothelioma and leukemia therapeutic models and pharmacokinetic studies in mice. The antibody with normal glycosylation mediated ADCC against hematopoietic and solid tumor cells at concentrations below 1 μg/ml, but the reduced fucosylated antibody was about 5-10 fold more potent
in vitro against multiple cancer cell lines, was more potent
in vivo against JMN mesothelioma, and effective against SET2 AML and fresh ALL xenografts. ESKM had a shortened half-life (4.9
vs 6.5 days), but an identical biodistribution pattern in C57BL6/J mice. At therapeutic doses of ESKM, there was no difference in half-life or biodistribution in HLA-A2.1 + transgenic mice compared to the parent strain. Importantly, therapeutic doses of ESKM in these mice caused no depletion of total WBCs or hematopoetic stem cells, or pathologic tissue damage.-
6.发明公开
公开(公告)号：EP4003373A1
公开(公告)日：2022-06-01
申请号：EP20843894.5
申请日：2020-07-24
发明人： YUN, Hongruo , CUI, Jun , ZHANG, Pengbo , XU, Yiyang , HORAN, Lucas , XU, Shaohua , XIONG, Guangyan , LI, Shan , XU, Yixiang , HELLER, Bradley Austin , ZHANG, Hongbing , LIU, Hong
IPC分类号： A61K35/17 , C07K14/705 , A61P35/00
-
公开(公告)号：EP3615574A1
公开(公告)日：2020-03-04
申请号：EP18791195.3
申请日：2018-04-24
发明人： ZHANG, Pengbo , XU, Yiyang , MORALES, Javier , NAKANO, Yoko , LIU, Hong , XIANG, Jingyi , ACKER, Timothy
IPC分类号： C07K16/30 , C07K16/46 , C07K19/00 , G01N33/574 , A61K39/395 , A61P35/00
-
公开(公告)号：EP3568468A1
公开(公告)日：2019-11-20
申请号：EP18739104.0
申请日：2018-01-11
发明人： CHAN, Vivien, Wai-Fan , LIU, Hong , NAKANO, Yoko , XU, Yiyang
IPC分类号： C12N5/0783 , C12N15/85 , C07K16/28 , C07K16/30 , A61K39/395 , G01N33/574
-
9.发明公开CONSTRUCTS TARGETING NY-ESO-1 PEPTIDE/MHC COMPLEXES AND USES THEREOF 审中-公开靶向NY-ESO-1肽/ MHC复合物的构建体及其用途
公开(公告)号：EP3313873A2
公开(公告)日：2018-05-02
申请号：EP16815452.4
申请日：2016-06-24
发明人： LIU, Cheng , LIU, Hong , XU, Yiyang , XIANG, Jingyi
IPC分类号： C07K14/705 , A61K39/395 , G01N33/574
CPC分类号： G01N33/57492 , C07K14/00 , C07K14/4748 , C07K16/2809 , C07K16/2833 , C07K16/3069 , C07K2317/21 , C07K2317/31 , C07K2317/32 , C07K2317/33 , C07K2317/34 , C07K2317/56 , C07K2317/622 , C07K2317/73 , C07K2317/92 , C07K2319/03 , G01N2333/70539
摘要： The present application provides constructs comprising an antibody moiety that specifically binds to a complex comprising an NY-ESO-1 peptide and an MHC class I protein. Also provided are methods of making and using these constructs.
-
公开(公告)号：EP3297671A2
公开(公告)日：2018-03-28
申请号：EP16797161.3
申请日：2016-05-17
发明人： WONG, Brian , MASTELLER, Emma , LIU, Cheng , XU, Yiyang , LIU, Hong , YAN, Su , XIANG, Jingyi , WANG, Pei
IPC分类号： A61K39/395 , C07K16/28 , C12N1/15 , C12N1/21 , G01N33/574
CPC分类号： C07K16/2803 , A61K38/05 , A61K47/6817 , A61K47/6851 , A61K47/6881 , A61K51/1027 , A61K51/1042 , A61K51/1096 , A61K2039/505 , A61P35/00 , A61P35/02 , C07K16/005 , C07K16/2809 , C07K16/30 , C07K2317/14 , C07K2317/21 , C07K2317/31 , C07K2317/34 , C07K2317/52 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C07K2317/732 , C07K2317/734 , C07K2317/76 , C07K2317/77 , C07K2317/92 , C07K2319/00 , G01N33/57492 , G01N2333/912
摘要： The invention relates to antibodies, and in particular, to antibodies exhibiting specificity for Receptor tyrosine kinase-like Orphan Receptors (ROR), and to uses thereof, for example in the treatment of cancer. The invention extends to polynucleotide and polypeptide sequences encoding the antibodies, and therapeutic uses thereof, and to diagnostic kits comprising these molecules. The invention also extends to antibody-drug conjugates and to uses thereof in therapy.
-
-
-
-
-
-
-
-
-
搜索结果
19 条记录 (耗时 0.029 秒)
